Literature DB >> 29463560

Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.

Matthias M Heck1, Margitta Retz2, Miriam Bandur2, Marc Souchay2, Elisabeth Vitzthum2, Gregor Weirich3, Tibor Schuster4, Michael Autenrieth2, Hubert Kübler2, Tobias Maurer2, Mark Thalgott2, Kathleen Herkommer2, Jürgen E Gschwend2, Roman Nawroth2.   

Abstract

Purpose: Molecular lymph node (LN) analysis using quantitative polymerase chain reaction (qPCR) detects LN metastases with higher sensitivity than histopathology. However, the prognostic role of molecular LN status in prostate cancer patients treated with radical prostatectomy (RP) and extended pelvic LN dissection (ePLND) is unclear. To investigate the association of molecular compared with histopathologic LN status with biochemical recurrence.Experimental Design: Patients with intermediate and high-risk prostate cancer were prospectively enrolled and underwent RP with ePLND, including the obturator, internal, external, and the common iliac region. LNs ≥3 mm were bisected and examined by standard histopathology and qPCR for Kallikrein3 (KLK3) expression. Biochemical recurrence was defined by confirmed postoperative PSA > 0.2 ng/mL.
Results: In 111 patients, 2,411 of 3,173 removed LNs were examined by both methods. Histopathology detected 68 LN metastases in 28 (25%) patients. Molecular analysis confirmed elevated KLK3 expression in 65 histopathologic LN metastases of all 28 pN1 patients (pN1/molN1) and additionally reclassified 224 histopathologic negative LNs and 32 (29%) pN0 patients as LN-positive (pN0/molN1).At a median follow-up of 48 months, 52 (47%) patients developed biochemical recurrence. Median biochemical recurrence-free survival was 9 months [95% confidence interval (CI), 0.0-20.1] in pN1/molN1 patients, 24 months (95% CI, 1.7-46.3) in pN0/molN1 patients and was not reached in pN0/molN0 patients (P < 0.001). On multivariable Cox regression analysis, molecular LN status [HR 4.1 (95% CI, 1.9-8.8), P < 0.001] but not histopathologic LN status [HR 1.5 (95% CI, 0.8-3.0), P = 0.198] was confirmed as independent predictor of biochemical recurrence.Conclusions: Molecular LN analysis identified pN0 patients with a high risk of biochemical recurrence and provided superior prognostic information in comparison with histopathology alone. Clin Cancer Res; 24(10); 2342-9. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID: 29463560     DOI: 10.1158/1078-0432.CCR-17-3771

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  4 in total

Review 1.  Prostate cancer: Molecular lymph node analysis for prognostication.

Authors:  Rebecca Kelsey
Journal:  Nat Rev Urol       Date:  2018-03-06       Impact factor: 14.432

2.  On the probability of lymph node negativity in pN0-staged prostate cancer-a theoretically derived rule of thumb for adjuvant needs.

Authors:  Frank Paulsen; Jens Bedke; Daniel Wegener; Jolanta Marzec; Peter Martus; Dominik Nann; Arnulf Stenzl; Daniel Zips; Arndt-Christian Müller
Journal:  Strahlenther Onkol       Date:  2021-09-02       Impact factor: 4.033

3.  Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy.

Authors:  Berna C Özdemir; Nicolas Arnold; Achim Fleischmann; Janine Hensel; Irena Klima; Marianna Kruithof-de Julio; Fiona Burkhard; Stefanie Hayoz; Bernhard Kiss; George N Thalmann
Journal:  Eur Urol Open Sci       Date:  2022-08-16

Review 4.  The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review.

Authors:  Peng Yuan; Shen Wang; Xiao Liu; Xinguang Wang; Zhangqun Ye; Zhiqiang Chen
Journal:  World J Surg Oncol       Date:  2020-01-20       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.